Clinical Trial Update: An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma [Phase 2]

View source ↗

Summary

Phase 2 open-label trial of lenvatinib in previously treated patients with unresectable stage III or stage IV melanoma completed; results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Unresectable Melanoma

Drugs mentioned

• Lenvatinib (lenvatinib)

Snippet

Sponsor: Eisai Inc. | Conditions: Unresectable Stage III, Stage IV Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2016-03-16